Skip to search formSkip to main contentSkip to account menu

galsulfase

Known as: ARSB, Arylsufatase B, galsulfase [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

6 relations
5 ML galsulfase 1 MG/ML Injection [Naglazyme]Alpha-glucosidaseSulfatasesanalogs & derivatives

Broader (2)

Arylsulfatase BRecombinant Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Long-Term Galsulfase Treatment Associated With Improved Survival of Patients With Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): 15-Year Follow-Up From the Survey Study
Mucopolysaccharidosis VI (MPS VI) is a progressive lysosomal storage disorder with multiorgan and multisystemic pathology… 
Review
2016
Review
2016
Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
BACKGROUND Mucopolysaccharidosis type VI or Maroteaux-Lamy syndrome is a rare genetic disorder caused by the deficiency of… 
2016
2016
Decline in arylsulfatase B leads to increased invasiveness of melanoma cells
Arylsulfatase B (ARSB; N-acetylgalactosamine 4-sulfatase) is reduced in several malignancies, but levels in melanoma have not… 
Review
2014
Review
2014
Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy syndrome)—10‐year follow‐up of patients who previously participated in an MPS VI survey study
Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder with multiorgan manifestations caused by… 
2013
2013
Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase
BackgroundMucopolysaccharidosis type VI (Maroteaux-Lamy syndrome; MPS VI) is an autosomal recessive lysosomal storage disorder in… 
2013
2013
Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
ObjectiveTo evaluate the efficacy and safety of two dose levels of galsulfase (Naglazyme®) in infants with MPS VI.Study… 
2008
2008
Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme®) therapy
MPS VI (mucopolysaccharidosis VI, known as Maroteaux–Lamy syndrome) is a multi-systemic inherited disease, resulting from a… 
2008
2008
Successful Management of Difficult Infusion-Associated Reactions in a Young Patient With Mucopolysaccharidosis Type VI Receiving Recombinant Human Arylsulfatase B (Galsulfase [Naglazyme])
Our patient with mucopolysaccharidosis type VI received enzyme replacement therapy with recombinant human arylsulfatase B… 
2008
2008
Development, Validation, and Clinical Implementation of an Assay to Measure Total Antibody Response to Naglazyme® (Galsulfase)
Naglazyme® (galsulfase, rhASB) was developed as enzyme replacement therapy for mucopolysaccharidosis type VI. Naglazyme generated… 
2008
2008
Comparison of Neutralizing Antibody Assays for Receptor Binding and Enzyme Activity of the Enzyme Replacement Therapeutic Naglazyme® (Galsulfase)
Most patients receiving Naglazyme® (galsulfase, rhASB) enzyme replacement therapy for mucopolysaccharidosis type VI develop an… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)